We're here for you and your family at our pediatric hospitals and care clinics – and at home.
As the COVID-19 omicron variant surges, Arkansas Children’s Innovation Center is postponing the 48-hour digital health challenge originally scheduled for late January and has set a new date of April 1-3.
Arkansas Children’s Innovation Center, in partnership with Arkansas entrepreneurial support organizations, will present a 48-hour digital health challenge featuring a $10,000 cash prize.
Arkansas Children’s Research Institute (ACRI) will be a key partner in a 14-state consortium focused on pediatric COVID-19 long haul cases, part of a massive nation-wide research effort funded by the National Institutes of Health (NIH).
A prospective open label, multicenter study to evaluate the feasibility and side effects of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days by mouth difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 twice daily on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Many people call them stork’s bite or angel’s kisses, but vascular birthmarks (medically called vascular anomalies) are abnormal blood vessels that people are born with. Most often, you’ll see them on a baby’s skin not long after they’re born. But they can also be found deeper than the skin and are discovered later in life as they grow.
Because of its benefits, one of the first children in line to get the COVID vaccine is that of infectious disease doctor, Jessica Snowden, M.D. Read her story.
We know that healthcare can be complicated, so we make it as easy as possible to access primary and specialty care.